Our History

In 2013, several of the scientists credited with discovering and developing CRISPR joined forces to establish what is now called Editas Medicine. Those scientists – Feng Zhang, George Church and Jennifer Doudna – along with fellow founders Keith Joung and David Liu, were focused on translating the new technology into therapies that enable precise and corrective molecular modification to treat people with a broad range of diseases at the genetic level.

In November 2013, Editas Medicine secured a $43 million Series A financing led by Flagship Pioneering, Polaris Partners and Third Rock Ventures, with participation from the Partners Innovation Fund, and assembled a strong leadership team and board of directors.

Exceptional People and Culture

The lifeblood of our company is our exceptional people and culture. We have purposefully built the team with a focus on passionate scientists and company-builders who have hands-on experience translating groundbreaking science into important new medicines.

Katrine Bosley
Katrine Bosley
Chief Executive Officer

Katrine joined Editas Medicine as President Chief Executive Officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Before Editas, she was Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was President and CEO of Avila Therapeutics. Earlier, Katrine was Vice President, Business Development at Adnexus Therapeutics, and she held several positions at Biogen in business development, commercial operations,...

Read More

Charles Albright, Ph.D.
Charles Albright, Ph.D.
Chief Scientific Officer

Charlie joined Editas Medicine as Chief Scientific Officer in August 2016. He brings more than 25 years of life sciences industry and academic leadership experience, most recently serving as vice president of genetically defined diseases and genomics at Bristol-Myers Squibb (BMS). Over his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as...

Read More

Gerald Cox, M.D., Ph.D.
Gerald Cox, M.D., Ph.D.
Chief Medical Officer

Gerry joined Editas Medicine as Chief Medical Officer in 2016. Previously, he held senior clinical development roles at Sanofi Genzyme (formerly Genzyme Corporation) for over 15 years, most recently as Vice President of Rare Disease Clinical Development. He was instrumental in the development and approval of treatments for lysosomal storage disorders, including the enzyme replacement therapies Aldurazyme® (iduronidase) for Mucopolysaccharidosis type I in 2003, Myozyme® (alglucosidase alfa) for Pompe disease in 2006, Elaprase® (idursulfase)...

Read More

Alexandra Glucksmann, Ph.D.
Alexandra Glucksmann, Ph.D.
Chief Operating Officer

Alexandra joined Editas Medicine in November 2013 and is the Chief Operating Officer. Prior to joining Editas Medicine, Alexandra was senior vice president of research and business operations from 2006 until June 2013 at Cerulean Pharma, a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. There, she was a founding employee and key contributor to all aspects of building the company, including setting strategy, analyzing product development opportunities, cultivating platform and product partnership...

Read More

Andrew Hack, M.D., Ph.D.
Andrew Hack, M.D., Ph.D.
Chief Financial Officer

Andrew joined Editas Medicine as CFO in July 2015. Previously, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Andrew was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career covering the biotechnology sector...

Read More

Timothy D. Hunt, J.D.
Timothy D. Hunt, J.D.
Senior Vice President of Corporate Affairs

Prior to joining Editas Medicine, Tim served as senior vice president of public affairs for Cubist Pharmaceuticals, before the company was acquired by Merck in 2015. Before joining Cubist, Tim spent several years at Biogen Idec, where he most recently served as vice president of public affairs, overseeing global communications. Previously, Tim also served in government affairs for GlaxoSmithKline, as well as for former Massachusetts governor, William F. Weld. Tim received his J.D. from the Columbus School of Law at the Catholic University...

Read More

Vic Myer, Ph.D.
Vic Myer, Ph.D.
Chief Technology Officer

Prior to joining Editas Medicine, Vic served as executive director and Cambridge site head for the developmental and molecular pathways department at the Novartis Institutes for Biomedical Research Incorporated (NIBR), where he also served as a research investigator, led the high-throughput biology team and oversaw the target discovery technologies platform. Vic was also a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array...

Read More

Kevin Bitterman, Ph.D.
Partner, Polaris Partners

Kevin Bitterman is a partner at Polaris Partners and has served as a member of the Editas board of directors since June 2014 and as president from November 2013 until June 2014. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics) and Morphic Rock. He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Direct Vet Marketing, Kala Pharmaceuticals, Morphic Rock Therapeutics, Neuronetics, Inc., TARIS Biomedical and Visterra Inc.

Kevin holds a Ph.D. in genetics from Harvard Medical School and a B.A in biological sciences from Rutgers College. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.

Read More

Alexis Borisy
Partner, Third Rock Ventures

Third Rock Ventures partner Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interim CEO, co-founded Blueprint Medicines, launched Warp Drive Bio and served as its interim CEO and currently is chairman of the company. Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its CEO and bringing the company public on the Nasdaq. He has raised more than $1 billion in financing and business development deals and he has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard, where he was a Howard Hughes pre-doctoral fellow, Mr. Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar. Mr. Borisy serves on the board of the Biotechnology Industry Organization, is an overseer at the Boston Museum of Science, is a co-founder and former Chairman of FORMA Therapeutics and serves on the board of Blueprint Medicines.

Mr. Borisy received his undergraduate degree in chemistry from the University of Chicago and completed graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University.

Read More

Katrine Bosley
Chief Executive Officer, Editas Medicine

Katrine joined Editas Medicine as President Chief Executive Officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Before Editas, she was Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was President and CEO of Avila Therapeutics. Earlier, Katrine was Vice President, Business Development at Adnexus Therapeutics, and she held several positions at Biogen in business development, commercial operations, and portfolio strategy. She was also part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University.

In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a Board member of Galapagos NV (EURONEXT and NASDAQ: GLPG) and of BIO – the Biotechnology Innovation Organization.

Read More

Douglas Cole, M.D.
General Partner, Flagship Pioneering

Douglas Cole is a partner at Flagship Pioneering, where he focuses on life science investments. At Flagship, Dr. Cole has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios Pharmaceuticals, Seventh Sense Biosystems and Avedro. He is a co-founder of Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics and Moderna Therapeutics. He currently serves on the board of directors of Tetraphase Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios, Selecta Biosciences and Avedro. Dr. Cole is a member of the scientific advisory board of the Spinal Muscular Atrophy Foundation, the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, the Scientific Advisory Board of the Massachusetts Life Sciences Center and serves on the board of directors of the Birch Rock Camp in Waterford, Maine. Earlier in his career, Dr. Cole was appointed instructor in neurology at Harvard Medical School and an assistant in neurology at Massachusetts General Hospital (MGH). He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the National Institutes of Health and several non-profit research foundations.

Dr. Cole holds an A.B. magna cum laude with high distinction from Dartmouth College and an M.D. from the University of Pennsylvania School of Medicine. He completed post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at MGH.

Read More

John D. Mendlein, Ph.D.
Chief Executive Officer, aTyr Pharma

John D. Mendlein, Ph.D., joined the Editas board of directors in January 2016. Since July 2010, he has served as Executive Chairman of aTyr Pharma, Inc., a public biopharmaceutical company and, since September 2011, he has also served as aTyr's Chief Executive Officer. Dr. Mendlein is Vice Chairman of the Board of Fate Therapeutics, Inc., a public biopharmaceutical company, and also serves on the boards of directors of Moderna Therapeutics, Inc. and Pronutria Biosciences, Inc., both private biopharmaceutical companies and BIO (Biotechnology Industry Organization) emerging companies board. From 2005 to 2008, Dr. Mendlein served as the Chief Executive Officer of Adnexus Therapeutics, Inc., a private biopharmaceutical company, which was purchased by Bristol-Myers Squibb Company in 2008. Dr. Mendlein also served on the board of directors of Monogram Biosciences, Inc., then a public HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009. Before that, he served as Chairman and CEO of Affinium Pharmaceuticals, Ltd., a private specialty pharmaceutical company (acquired by Debiopharm Group), from 2000 to 2005, and as a director, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation, then a public drug discovery company (acquired by Vertex Pharmaceuticals), from August 1996 to September 2001.

Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.

Read More

Boris Nikolic, M.D.
Managing Director, bng0

Boris Nikolic has served as a member of the Editas board of directors since August 2015. Dr. Nikolic has served as managing partner of investment fund bng0, LLC since February 2015 and as Managing Partner of investment fund Biomatics Capital since April 2014. From April 2009 to April 2014, he served as Chief Advisor for Science and Technology to Bill Gates at bgC3. From 2002 to 2010, Dr. Nikolic was an assistant professor at Harvard Medical School. He currently serves on the board of directors of BlueTalon, Inc. and Digisight Technologies, Inc., both private software companies, and Omniome, Inc., a private biotechnology company. He previously served on the board of directors of Schrödinger, LLC, a private chemical simulation software company. His academic research at Harvard Medical School focused on the field of immunogenetics and translational immunology. Dr. Nikolic has received numerous national and international awards and managed international teams of scientists. He has been selected as a field expert scientist for peer review committees, study sections, and professional associations. Dr. Nikolic is the author of more than 70 articles, patents, and patent applications, and he is co-founder of three biotechnology companies.

Dr. Nikolic earned his M.D. from the Zagreb Medical School in Zagreb, Croatia and completed his postdoctoral fellowship in transplantation immunology at Harvard Medical School.

Read More

Akshay Vaishnaw, M.D., Ph.D.
Executive Vice President of Research and Development and Chief Medical Officer at Alnylam Pharmaceut

Executive Vice President of Research and Development and Chief Medical Officer at Alnylam Pharmaceuticals, Inc. joined our board of directors in July 2016. He has served as Alnylam’s Executive Vice President of Research and Development since December 2014 and as their Chief Medical Officer since June 2011. Dr. Vaishnaw also served Alnylam in a number of senior R&D roles of increasing responsibility since joining the company in 2006. From December 1998 through 2005, he held various positions at Biogen Inc.

Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in molecular immunology. He is also a Fellow of the Royal College of Physicians, U.K. He serves on the board of directors of Visterra Inc., and the scientific advisory board of Scholar Rock Inc.

Read More

Feng Zhang, Ph.D.
Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation

Feng Zhang joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Dr. Zhang is a Searle Scholar and has received both a Director’s Transformative Research Award and a Directors? Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.

Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.

Read More

George Church, Ph.D.
Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering

George Church is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. Dr. Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Dr. Church pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. Dr. Church has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.

Dr. Church holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.A. in zoology and chemistry from Duke University.

Read More

J. Keith Joung, M.D., Ph.D.
Associate Chief of Pathology for Research and Pathologist, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School

J. Keith Joung currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.

Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.

Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.

Read More

David R. Liu, Ph.D.
Investigator, Howard Hughes Medical Institute; Professor of Chemistry and Chemical Biology, Harvard University; Vice-Chair of the Faculty and Core Faculty Member, Broad Institute of MIT and Harvard

David R. Liu is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute investigator, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and MIT. His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and genome editing.  Dr. Liu’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the U.S. government on matters of science and technology. Dr. Liu is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation (NSF) Faculty Early Career Development (CAREER) Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. Dr. Liu was named to the Popular Science “Brilliant 10” for young scientists in the U.S., as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology.  His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.

Dr. Liu holds a B.A. in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley. 

Read More